IP Library › Granted Patent US 12,611,540
Granted Patent B2
US 12,611,540 · App. 18/051,425 · Granted Apr 28, 2026

Modulation of growth differentiation factor 10 (GDF10)

Inventors: Howard J. Leonhardt (Mission Viejo, CA); Kelsie Leonhardt (Mission Viejo, CA)
Assignee: LEONHARDT VENTURES LLC
A61N1/326A61N1/37205A61M5/14276A61M2202/07A61M2205/05
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,611,540
App. No.
18/051,425
Granted
Apr 28, 2026
Kind
B2
Abstract

Described is a low voltage, pulsed electrical stimulation device for controlling expression of growth differentiation factor 10 (“GDF10”), a useful protein, by tissues. Also described are methods of enhancing expression of GDF10 in cells, particularly a method of stimulating the expression and/or release of GDF10 in a cell having a gene encoding GDF10, wherein the method includes applying a bioelectric signal produces, as measured at the level of the target cells or tissues being stimulated 2 mA to 4 mA direct current positive to the cell (e.g., directly, indirectly, or wirelessly). Applications in the treatment of cerebral strokes, brain injuries, paralysis, brain cancer, Alzheimer's disease, dementia, anxiety, Parkinson's disease, and/or essential tremors are also disclosed.

Claims (9)

1 . A method of stimulating an expression of growth differentiation factor 10 (GDF10) in a cell having a gene encoding GDF10, wherein the method comprises:

applying to the cell a first bioelectric signal of 2 mA to 3 mA direct current positive polarity;

measuring, at the cell to which the first bioelectric signal is being applied, the applied first bioelectric signal; and

applying a separate bioelectric signal to the cell that upregulates expression of brain-derived neurotrophic factor (BDNF) in the cell,

wherein the amount of GDF10 expression by the cell is enhanced by the first bioelectric signal.

2 . The method according to claim 1 , wherein the first bioelectric signal is 3 mA direct current positive polarity.

3 . The method according to claim 1 , wherein the cell is located in tissue selected from the group consisting of brain, inner ear, uterus, prostate, neural tissue(s), blood vessels, adipose tissue, spleen, liver, bone, cochlea, lung, testis, retina, and pineal gland.

4 . The method according to claim 1 , further comprising:

selecting a subject suffering from cerebral stroke, brain injury, paralysis, brain cancer, Alzheimer's disease, dementia, anxiety, Parkinson's, and/or essential tremors, and wherein the cell is located in tissue in the subject.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 18, 2023
From: LEONHARDT, HOWARD J.; LEONHARDT, KELSIE
To: LEONHARDT VENTURES LLC
Reel/Frame 062414/0795 →
Continuity (2)
Provisional Application 63274387 · Nov 1, 2021
Related Publication 20230133737A1 · May 4, 2023
References Cited (22)
US 8442653B2 · Gill · 2013 [cited by applicant]
US 9700596B2 · Carmichael et al. · 2017 [cited by applicant]
US 10960206B2 · Leonhardt et al. · 2021 [cited by applicant]
US 20080208287A1 · Palermo · 2008 [cited by examiner]
US 20190329033A1 · Li · 2019 [cited by examiner]
US 20200000709A1 · Leonhardt et al. · 2020 [cited by applicant]
US 20200289826A1 · Leonhardt · 2020 [cited by applicant]
US 20230071154A1 · Leonhardt · 2023 [cited by examiner]
WO WO2020041705 · 2020 [cited by examiner]
American Heart Association, “Naturally occurring protein to block inflammatory response improved stroke recovery in mice” (Sep. 22, 2021), Medical Express (Cardiology); medicalxpress.com/news/2021-09-naturally-protein-b… [cited by applicant]
Chen “A potential treatment of COVID-19 with TGF-ß blockade.” Int J Biol Sci. Apr. 21, 2020; 16(11):1954-1955. Doi: 10.7150/ijbs.46891. PMID: 32398962; PMCID: PMC7211163. [cited by applicant]
Ghazavi et al. “Cytokine profile and disease severity in patients with COVID-19”. Cytokine. Sep. 30, 2020; 137:155323. Doi: 10.1016/j.cyto.2020.155323. Epub ahead of print. PMID: 33045526; PMCID: PMC7524708. [cited by applicant]
Jiang et al. “A guinea pig IFNA1 gene with antiviral activity against human influenza virus infection.” Front Biosci (Landmark Ed). Mar. 1, 2019; 24:790-797. PMID: 30844713. [cited by applicant]
Kennedy et al. “Impaired innate, humoral, and cellular immunity despite a take in smallpox vaccine recipients.” Vaccine. Jun. 14, 2016; 34(28):3283-90. Doi: 10.1016/j.vaccine.2016.05.005. Epub May 11, 2016. PMID: 271779… [cited by applicant]
Koti et al. “BCG vaccine and COVID-19: implications for infection prophylaxis and cancer immunotherapy.” J Immunother Cancer. Jul. 2020; 8(2):e001119. Doi: 10.1136/jitc-2020-001119. PMID: 32636240; PMCID: PMC7342862. [cited by applicant]
Kumar et al. “Human Sertoli cells support high levels of Zika virus replication and persistence.” Sci Rep. Apr. 3, 2018; 8(1):5477. doi: 10.1038/s41598-018-23899-x. PMID: 29615760; PMCID: PMC5883016. [cited by applicant]
Li, et al. “GDF10 is a signal for axonal sprouting and functional recovery after stroke,” Nature Neuroscience, 2015; doi: 10.1038/nn.4146. [cited by applicant]
Limonta et al. “Fibroblast Growth Factor 2 Enhances Zika Virus Infection in Human Fetal Brain.” J Infect Dis. Sep. 13, 2019; 220(8):1377-1387. doi: 10.1093/infdis/jiz073. PMID: 30799482; PMCID: PMC6743838. [cited by applicant]
McGowan et al. “Targeting the SphK-S1P-SIPR Pathway as a Potential Therapeutic Approach for COVID-19.” Int J Mol Sci. Sep. 29, 2020; 21(19):7189. Doi: 10.3390/ijms21197189. PMID: 33003377; PMCID: PMC7583882. [cited by applicant]
Meini et al. “Intussusceptive angiogenesis in Covid-19: hypothesis on the significance and focus on the possible role of FGF2.” Mol Biol Rep. Oct. 2020; 47(10):8301-8304. Doi: 10.1007/s11033-020-05831-7. Epub Sep. 12, 2… [cited by applicant]
U.S. Appl. No. 63/237,682, filed Aug. 27, 2021, to Leonhardt et al. for “Modulation of Brain-Derived Neurotrophic Factor (BDNF)”. [cited by applicant]
Zhang et al. “Discharge may not be the end of treatment: Pay attention to pulmonary fibrosis caused by severe COVID-19.” J Med Virol. Oct. 27, 2020. Doi: 10.1002/jmv.26634. Epub ahead of print. PMID: 33107641. [cited by applicant]